<SEC-DOCUMENT>0001213900-25-100779.txt : 20251021
<SEC-HEADER>0001213900-25-100779.hdr.sgml : 20251021
<ACCEPTANCE-DATETIME>20251021154039
ACCESSION NUMBER:		0001213900-25-100779
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20251021
FILED AS OF DATE:		20251021
DATE AS OF CHANGE:		20251021

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Inspira Technologies OXY B.H.N. Ltd
		CENTRAL INDEX KEY:			0001837493
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		EIN:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40303
		FILM NUMBER:		251406894

	BUSINESS ADDRESS:	
		STREET 1:		HATIDHAR 2
		STREET 2:		11TH FLOOR
		CITY:			RA'ANANA
		STATE:			L3
		ZIP:			4366504
		BUSINESS PHONE:		972-9-9664488

	MAIL ADDRESS:	
		STREET 1:		HATIDHAR 2
		STREET 2:		11TH FLOOR
		CITY:			RA'ANANA
		STATE:			L3
		ZIP:			4366504
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>ea0261918-6k_inspira.htm
<DESCRIPTION>REPORT OF FOREIGN PRIVATE ISSUER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 6-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REPORT OF FOREIGN PRIVATE ISSUER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURSUANT TO RULE 13a-16 OR 15d-16</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>For the Month of October 2025 (Report No. 2)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Commission File Number: 001-40303</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Inspira Technologies Oxy B.H.N. Ltd.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Translation of registrant&rsquo;s name into
English)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>2 Ha-Tidhar St.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Ra&rsquo;anana 4366504, Israel</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Address of principal executive office)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#9746;&nbsp;Form 20-F&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9744;&nbsp;Form
40-F</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>CONTENTS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On October 21, 2025, Inspira Technologies
Oxy B.H.N. Ltd. (the &ldquo;Company&rdquo;) issued a press release titled &ldquo;Inspira Appoints Former Johnson &amp; Johnson Senior
Business Manager as VP of Global Sales and New Board Member from a Leading International Investment Firm,&rdquo; a copy of which is furnished
as Exhibit 99.1 with this report of foreign private issuer on Form 6-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="background-color: white">The
first, second and third paragraphs and the section titled &ldquo;Forward-Looking Statements&rdquo; in the&nbsp;press release are incorpora</FONT>ted
<FONT STYLE="background-color: white">by reference into the Company&rsquo;s Registration Statements on Form&nbsp;F-3 (Registration Nos.
</FONT><A HREF="https://www.sec.gov/Archives/edgar/data/1837493/000121390022046430/ea164081-f3_inspiratech.htm"><FONT STYLE="background-color: white">333-266748</FONT></A><FONT STYLE="background-color: white">,
</FONT><A HREF="https://www.sec.gov/Archives/edgar/data/1837493/000121390025004023/ea0227763-f3_inspira.htm"><FONT STYLE="background-color: white">333-284308</FONT></A>
<FONT STYLE="background-color: white">and </FONT><A HREF="https://www.sec.gov/Archives/edgar/data/1837493/000121390025072618/ea0251967-f3_inspira.htm"><FONT STYLE="background-color: white">333-289324</FONT></A><FONT STYLE="background-color: white">)
and Form&nbsp;S-8 (Registration Nos. </FONT><A HREF="https://www.sec.gov/Archives/edgar/data/1837493/000121390021044780/ea146415-s8_inspiratech.htm"><FONT STYLE="background-color: white">333-259057</FONT></A><FONT STYLE="background-color: white">,
</FONT><A HREF="https://www.sec.gov/Archives/edgar/data/1837493/000121390024023044/ea0201791-s8_inspira.htm"><FONT STYLE="background-color: white">333-277980</FONT></A>,
<A HREF="https://www.sec.gov/Archives/edgar/data/1837493/000121390025020699/ea0233153-s8_inspira.htm">333-285565</A> <FONT STYLE="background-color: white">and
<A HREF="http://www.sec.gov/Archives/edgar/data/1837493/000121390025086563/ea0254938-s8_inspira.htm">333-290162</A>), filed with the Securities and Exchange Commission, to be a part thereof from the date on which this report is submitted,
to the extent not superseded by documents or reports subsequently filed or furnished.</FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top; width: 8%; border-bottom: black 1.5pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit No.</B></FONT></TD>
    <TD STYLE="vertical-align: top; width: 1%; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 91%; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ea026191801ex99-1_inspira.htm">Press Release issued by Inspira Technologies Oxy B.H.N. Ltd. on October 21, 2025, titled &ldquo;Inspira Appoints Former Johnson &amp; Johnson Senior Business Manager as VP of Global Sales and New Board Member from a Leading International Investment Firm.&rdquo;</A></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>SIGNATURES</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Inspira Technologies Oxy B.H.N. Ltd.</B></FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: October 21, 2025</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Dagi Ben-Noon</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;</FONT>&nbsp;</TD>
    <TD STYLE="width: 32%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dagi Ben-Noon</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea026191801ex99-1_inspira.htm
<DESCRIPTION>PRESS RELEASE ISSUED BY INSPIRA TECHNOLOGIES OXY B.H.N. LTD. ON OCTOBER 21, 2025, TITLED "INSPIRA APPOINTS FORMER JOHNSON & JOHNSON SENIOR BUSINESS MANAGER AS VP OF GLOBAL SALES AND NEW BOARD MEMBER FROM A LEADING INTERNATIONAL INVESTMENT FIRM."
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="ex99-1_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Inspira Appoints Former Johnson &amp; Johnson
Senior Business Manager as VP of Global Sales and New Board Member from a Leading International Investment Firm</B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">RA&rsquo;ANANA, Israel, October 21, 2025 -- Inspira&trade; Technologies OXY
B.H.N. Ltd. (NASDAQ: IINN) (&ldquo;<B>Inspira,</B>&rdquo; <B>&ldquo;Inspira Technologies</B>,&rdquo; or the &ldquo;<B>Company</B>&rdquo;),
a pioneer in innovative life-support and diagnostic technologies, today announced two key leadership appointments that reinforce its global
commercialization and governance &ndash; the appointment of Mr. Mike Hershkovitz as Vice President of Global Sales of the Company and
the appointment of Ms. Sivan Matza as a member of the board of directors of the Company (the &ldquo;Board&rdquo;). The Board appointed
Ms. Matza to serve as an independent director of the Company until the next annual general meeting of the Company&rsquo;s shareholders.
Ms. Matza will also serve as a member of the Board&rsquo;s compensation committee, audit committee and financial statement examination
committee. Ms. Matza will succeed Ms. Limor Rosen, who is stepping down from the Board.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">Ms. Sivan Matza is a Director at a leading international investment
management firm overseeing tens of billions of dollars in assets. Her extensive experience in global finance, regulation and accounting
strengthens Inspira&rsquo;s governance framework as the Company accelerates its commercial expansion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">Mr. Mike Hershkovitz, based in the United States, has been appointed
Vice President of Global Sales. Mr. Hershkovitz brings nearly two decades of leadership in U.S. and international healthcare markets,
including senior commercial roles at Johnson &amp; Johnson and other global med-tech organizations. He will lead Inspira&rsquo;s sales
strategy and hospital adoption initiatives worldwide.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dagi
Ben-Noon, CEO of Inspira Technologies, commented: &ldquo;The addition of Sivan and Mike to our leadership team is a strategic step that
meaningfully enhances Inspira&rsquo;s capabilities. Sivan&rsquo;s experience in international finance and regulation from a top-tier
firm is an invaluable asset as we expand our operations and strengthen our governance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
parallel, Mike&rsquo;s proven leadership in sales and commercial management, including his tenure at Johnson &amp; Johnson, together
with his strong understanding of the med-tech industry, will drive our commercial strategy and speed the adoption of our technologies
in hospitals worldwide. Their combined expertise is a powerful catalyst for Inspira&rsquo;s next phase of growth and execution.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company also extended its appreciation to Ms. Limor Rosen, who is stepping down from the Board of Directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;We thank Limor for her contribution and commitment to Inspira&rsquo;s
vision and wish her continued success and welcome Sivan to the Board,&rdquo; stated Tal Parnes, chairman of the Board.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
Inspira Technologies</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inspira
Technologies is a commercial-stage medical device company specializing in advanced respiratory support and real-time blood monitoring
solutions. The Company&rsquo;s U.S. Food and Drug Administration -cleared INSPIRA&trade; ART100 system is approved for cardiopulmonary
bypass in the U.S. and ECMO (Extracorporeal Membrane Oxygenation) procedures outside the U.S and serves as a foundation for the development
of the INSPIRA ART500, a next-generation system designed to deliver oxygenation while patients remain awake and spontaneously breathing.
Inspira Technologies is also advancing HYLA&trade;, a proprietary blood sensor platform offering continuous, non-invasive monitoring.
With multiple cleared products, a growing IP portfolio, and strategic streamlining of its operations, Inspira Technologies is increasingly
positioned as an attractive platform within the life-support and MedTech landscape. The Company&rsquo;s recent internal shifts may reflect
broader alignment with long-term industry trends, including consolidation, cross-sector collaboration, and potential strategic partnerships.
For more information, visit: https://inspira-technologies.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Forward-Looking
Statement Disclaimer</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">This press release contains express or implied forward-looking statements
pursuant to U.S. Federal securities laws. These forward-looking statements are based on the current expectations of the management of
the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those
described in the forward-looking statements. For example, the Company is using forward-looking statements when it discusses the reinforcement
of its global commercialization and governance following the new appointments, the strengthening of the Company&rsquo;s governance framework
as the Company accelerates its commercial expansion, the potential of the appointments in leading the Company&rsquo;s commercial strategy
and acceleration of its technology&rsquo;s adoption in hospitals and the combined expertise serving as a powerful catalyst that will bolster
the Company as it enters its next phase of accelerated growth and execution. These forward-looking statements and their implications are
based solely on the current expectations of the Company&rsquo;s management and are subject to a number of factors and uncertainties that
could cause actual results to differ materially from those described in the forward-looking statements. Except as otherwise required by
law, the Company undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances
after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties
affecting the Company is contained under the heading &ldquo;Risk Factors&rdquo; in the Company&rsquo;s annual report on Form 20-F for the fiscal
year ended December 31, 2024, filed with the U.S. Securities and Exchange Commission (the &ldquo;SEC&rdquo;), which is available on the
SEC&rsquo;s website at www.sec.gov.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Company
Contact</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inspira
Technologies &ndash; Media Relations<BR>
Email: info@inspirao2.com<BR>
Phone: +972-9-9664485&nbsp;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  Z +L# 2(  A$! Q$!_\0
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MY%S?&?\ ;2NM1^'\<4VFZ/;Z[-KNEW\_BG2T\':-!XW^'T/@3POJ>AZE?_\
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$@#__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
